Buscar resultados de ensayos clínicos
Malignant Carcinoid Syndrome - 25 Studies Found
Estado | Estudiar |
Completed |
Nombre del estudio: Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy Condición: Carcinoid Syndrome Fecha: 2009-02-25 Intervenciones:
|
Completed |
Nombre del estudio: A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea Condición:
Fecha: 2010-10-20 |
Completed |
Nombre del estudio: An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males Condición: Carcinoid Syndrome Fecha: 2013-08-27 Intervenciones: Drug: 500 mg [14C]-LX1606 500 mg dose of LX1606 containing a target dose of 3.32 Megabecquerel (MBq) of |
Completed |
Nombre del estudio: Azilect + Antidepressant Chart Review Condición: Serotonin Syndrome Fecha: 2009-08-06 Intervenciones:
|
Completed |
Nombre del estudio: Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor Condición:
Fecha: 2006-12-13 Intervenciones:
|
Terminated |
Nombre del estudio: P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome Condición: Neuroendocrine Carcinoma Fecha: 2013-06-21 Intervenciones: Drug: Octreotide LAR Octreotide LAR as outlined in Treatment Arm. |
Completed |
Nombre del estudio: Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors Condición:
Fecha: 1999-11-01 Intervenciones:
|
Withdrawn |
Nombre del estudio: Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors Condición:
Fecha: 2005-09-26 Intervenciones:
|
Active, not recruiting |
Nombre del estudio: Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors Condición:
|
Completed |
Nombre del estudio: Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors Condición:
Fecha: 2003-03-06 Intervenciones: |